Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

17.1%

7 terminated/withdrawn out of 41 trials

Success Rate

82.1%

-4.5% vs industry average

Late-Stage Pipeline

37%

15 trials in Phase 3/4

Results Transparency

75%

24 of 32 completed trials have results

Key Signals

24 with results

Enrollment Performance

Analytics

Phase 4

14(41.2%)

N/A

9(26.5%)

Phase 1

6(17.6%)

Phase 2

4(11.8%)

Phase 3

1(2.9%)

34Total

Phase 4(14)

N/A(9)

Phase 1(6)

Phase 2(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (41)

Showing 20 of 41 trials

NCT01107717Phase 4Completed

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

Role: collaborator

NCT01364584Not ApplicableCompleted

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Role: collaborator

NCT01154933Phase 2Completed

Exeantide in Type 2 Diabetes on Insulin

Role: collaborator

NCT00882050Phase 1Completed

Intravenous Exenatide (Byetta) During Surgery

Role: collaborator

NCT00732147Not ApplicableWithdrawn

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

Role: collaborator

NCT00790699Not ApplicableTerminated

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

Role: collaborator

NCT01061775Phase 1Completed

Effects of Exenatide on Hypothalamic Obesity

Role: collaborator

NCT01268644Phase 1Terminated

Effects of Metreleptin in Type 1 Diabetes Mellitus

Role: collaborator

NCT00461552Phase 2Completed

Therapeutic Approaches to HAART-Induced Lipodystrophy

Role: collaborator

NCT00690235Phase 4Completed

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Role: collaborator

NCT00457938Not ApplicableCompleted

Novel Therapies for Metabolic Complications of Lipodystrophies

Role: collaborator

NCT01165944Phase 1Withdrawn

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

Role: collaborator

NCT00442767Phase 4Completed

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

Role: collaborator

NCT00353834Phase 4Completed

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

Role: collaborator

NCT01588418Phase 4Completed

Acute Effect of Exenatide on Brain Glucose Metabolism

Role: collaborator

NCT01501084Phase 1Completed

Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women

Role: collaborator

NCT00456885Phase 4Completed

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

Role: collaborator

NCT00529204Phase 2Terminated

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

Role: collaborator

NCT01381926Phase 4Terminated

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Role: collaborator

NCT00855439Not ApplicableCompleted

Evaluation of Exenatide in Patients With Diabetic Neuropathy

Role: collaborator